Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 12/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485269 | 0.91 | PCNA (0.74) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL16124458 | 0.88 | PCNA (0.74) | PCNAPOLBTHRATHRBHIF1A | |
| SCHEMBL16126005 | 0.85 | PCNA (0.81) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL14485257 | 0.82 | PCNA (0.61) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL14485308 | 0.81 | PCNA (0.77) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL16124453 | 0.78 | PCNA (0.78) | PCNAPOLBTHRATHRBHIF1A | |
| SCHEMBL16124445 | 0.77 | PCNA (0.56) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL16124422 | 0.76 | PCNA (0.56) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL16126006 | 0.75 | PCNA (1.00) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL5742010 | 0.75 | PCNA (0.57) | PCNAPOLBTHRATHRBHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | MKI67, PCNA, PCLAF | PCNA 2/4885POLB 300/4885THRA 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.